Navigation Links
ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
Date:4/23/2008

p>

ImaRx Therapeutics is a biopharmaceutical company commercializing and developing therapies for vascular disorders. The Company's commercialization efforts are currently focused on its product, urokinase for the treatment of acute massive pulmonary embolism. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology.

About Urokinase

In 2006, ImaRx acquired urokinase and all related assets, including approximately a four-year supply of inventory as well as cell lines and manufacturing rights to the drug. Since October 2006, ImaRx has been selling its urokinase inventory in the U.S. market, where it is estimated to be listed on pharmacy formularies at approximately 700 acute care hospitals.

Urokinase is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism, or blood clots in the lungs. The product has been commercialized for more than 20 years and has been administered to greater than four million patients.

Forward Looking Statements

Statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks related to our ability to successfully commercialize urokinase and other important risks relating to the Company's business, prospects, financial condition and results of operations that are discussed in the Section titled "Risk Factors" in the Company's Annual Report on Form 10-K/A for the year ended December 31, 2007, which has been filed with the SEC.

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

sephra
'/>"/>

SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
2. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
3. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
4. ImaRx to Report Corporate Updates and 4Q07 Financial Results
5. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
6. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
7. CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
8. Cell Therapeutics, Inc. Announces Receipt of Letter From the NASDAQ Stock Market Regarding Non-Compliance With the Minimum Bid Price Requirement
9. BioSpace and IBC Life Sciences Announce Career Fair Alliance For Drug Discovery & Development of Innovative Therapeutics World Congress
10. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
11. CV Therapeutics Announces $185 Million Transaction with TPG-Axon Capital for Half of Royalty for Lexiscan(TM) (regadenoson) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
(Date:8/20/2014)... Not long ago, it was more or ... late in the development cycle – even after the ... suggest that, like many things GxP, expectations for early ... multiple drug sponsors have been required by authorities to ... phase I/II. It’s not only clinical trial material containers ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 ... released today including improvements to the enterprise replication ... connectors for Lucene, SOLR and Elasticsearch. This release ... this high performance triplestore – GraphDB™ was formerly ... in deploying the only mature enterprise resilient RDF ...
(Date:8/19/2014)... , Aug. 19, 2014 A Geisinger researcher ... nominated for a Centers for Disease Control and Prevention ... major public health concern. Joseph Boscarino ... one of a team of researchers nominated for the ... Shepard Science Award for Data Methods and Study Design. ...
Breaking Biology Technology:New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... , , SANTA CLARA, Calif., Sept. 8 ... Board: APNO) today announced that they have entered into a ... Cell Biosciences for $1.50 per share or approximately $17.9 million ... analysis business to include a global infrastructure and a broad ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- Jiangbo,Pharmaceuticals, ... pharmaceutical company with its principal operations in the People,s,Republic ... year 2009. The Company expects to meet or ... and operating income of $40 to $43 million for ...
... , , ... systems biology tools company, announced today that Proteostasis Therapeutics has ... Therapeutics is the first company dedicated to the discovery of ... Network. The Proteostasis Network maintains the body,s natural balance ...
Cached Biology Technology:Cell Biosciences Signs Agreement to Acquire Alpha Innotech 2Cell Biosciences Signs Agreement to Acquire Alpha Innotech 3Cell Biosciences Signs Agreement to Acquire Alpha Innotech 4Cell Biosciences Signs Agreement to Acquire Alpha Innotech 5Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2GeneGo Licenses MetaCore to Proteostasis Therapeutics 2
(Date:8/20/2014)... visible in in this image of the Para and ... were most likely intentionally set in order to deforest ... or stand of trees where the land is thereafter ... conversion of forestland to farms, ranches, or urban use. ... of the Amazon Rainforest in the middle of the ...
(Date:8/20/2014)... acral melanomas the rare type of skin cancer that ... from other more common types of skin cancer, according to ... Pigment Cell & Melanoma Research . , Acral melanoma most ... feet, nail-beds and other hairless parts of the skin. Unlike ... UV damage from the sun. , The team, from the ...
(Date:8/20/2014)... During the past few years, Virginia Tech,s Wu Feng ... Microsoft grant from the "Computing in the Cloud" program, ... a $6 million award from the Air Force on ... from NSF and the National Institutes of Health on ... wove together the "parallel computing" aspects from each grant, ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2The internet was delivered to the masses; parallel computing is not far behind 2The internet was delivered to the masses; parallel computing is not far behind 3The internet was delivered to the masses; parallel computing is not far behind 4
... 2008) A new study by the Bronx Zoo-based ... the Greater Yellowstone Ecosystem have apparently hopped into oblivion. ... of the journal Oryx, also speculates that the disappearance ... a variety of other prey species and their predators. ...
... crucial proteins in our bodies must fold into complex shapes ... to move them around, to speed up important chemical reactions ... "off" to affect which proteins our cells make. Recently, ... genetic code into protein-can act a lot like a protein ...
... of shrimp and fish in tropical coastal areas is ... poverty, but in fact this cultivation has negative consequences ... Daniel A. Bergquist of Uppsala University, Sweden, has studied ... The cultivating of fish and shellfish in artificial ...
Cached Biology News:Hareless: Yellowstone's rabbits have vanished, study says 2Stanford researchers make first direct observation of 3-D molecule folding in real time 2Stanford researchers make first direct observation of 3-D molecule folding in real time 3Stanford researchers make first direct observation of 3-D molecule folding in real time 4Stanford researchers make first direct observation of 3-D molecule folding in real time 5Global trade in tiger shrimp threatens environment 2
... Ultrapure ACS Reagent Grade C 19 ... Formula Weight: 691.95 PRODUCT SPECIFICATIONS Form: Powder ... Interval: pH 3.0 - Yellow ... a tracking dye in agarose and acrylamide ...
... reads and processes raw microarray ... data for analysis. ,Package ... 1-year license for Feature Extraction ... CD-ROM containing Feature Extraction software ...
... Feature Extraction Software reads and ... to prepare microarray data for ... one 1-year license for ... accounts , * one ...
... 4 H 10 O 2 S ... SPECIFICATIONS Form: White crystalline powder Assay: ... Identity: By IR Melting Point: greater ... DTT: less than or equal to ...
Biology Products: